Faculty in the Department of Medicinal Chemistry and Pharmacognosy
Bolton, Judy L.: Professor and Head, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1988) University of Toronto
Research interests: Chemical toxicology. The
toxic effects elicited by dietary constituents often involves
oxidative metabolism to electrophilic intermediates. We utilize
chemical and biological approaches to study the cytotoxic/genotoxic
mechanism including synthesis, spectroscopy, chromatography and
enzymology. Metabolites and metabolic intermediates are identified,
and their effects on various biochemical parameters studied.
Bruzik, Karol S.: Associate Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1980) Polish Academy of Sciences
Research interests: Bioorganic chemistry. Investigation
of mechanisms of inositol-related enzymes and their function in
cell signaling events. Synthesis of analogs of biophosphates as
inhibitors and probes of enzyme mechanisms. Real-time, live-cell
assay of enzymatic activities in response to receptor stimulation.
Isolation, structure determination and synthesis of novel phosphoinositide
Burdette, Joanna E.: Associate Professor, Department of Medicinal Chemistry and Pharmacognosy. Ph.D. (2003) University of Illinois at Chicago
Research interests: The Burdette lab is interested in biological questions that are important for women’s health. We integrate imaging, drug discovery, and basic biology to try and understand how and where ovarian cancers originate. Our research primarily uses mouse models to understand early events in ovarian cancers. We are also using natural products to uncover new progestins and anti-cancer molecules.
Che, Chun-Tao: Norman R. Farnsworth Professor of Pharmacognosy, Department of Medicinal Chemistry and Pharmacognosy. Ph.D. (1982) University of Illinois at Chicago
Research interests: Interested in natural drugs and Chinese medicine, including:
1. Natural products chemistry: isolation, characterization, and structural elucidation of secondary metabolites from medicinal plants and other natural sources. 2. Biologically active natural substances.
3. Chemical/biological standardization and quality assessment of herbal drugs and herb-based preparations.
4. Development of analytical techniques for herbal drug analysis.
5. Development of evidence-based Chinese medicine and other natural products
Federle, Michael J.: Assistant Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (2002) Emory University, Atlanta
Research interests:Research focuses on discovering and understanding how bacteria communicate among themselves as a means for organizing group behaviors, especially behaviors facilitating the initiation and progression of disease in humans. Cell-to-cell communication in bacteria, termed Quorum Sensing, relies on a language of small, secreted signaling molecules called autoinducers. Bacteria detect and respond to autoinducers through various types of receptor proteins sitting atop gene regulatory networks. it is my goal to identify and describe the production and structure of new autoinducers and their cognate signal-transduction networks that contribute to the pathogenic state of the microorganism. Our lab will use classic bacterial genetic and molecular biology techniques combined with conventional genomic, proteomic, and metabolomic analyses to identify components and targets of these signaling systems. Structural analysis of autoinducers and receptors, as well as screening for inhibitory compounds, will also be a focus of our work. I am concentrating my efforts on Gram-positive pathogens, as these organisms pose the most current threat in developing resistance to multiple antibiotic treatments. It is my hope that our research will lead to the development of new therapies that exploit and confuse communication systems bacteria use to organize attacks on the body.
Franzblau, Scott, G.: Professor and Director of the Institute for Tuberculosis Research, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1982) University of Arizona
Research interests: New drug discovery from
natural and synthetic sources for tuberculosis; high throughput
screening assay development; new drug target identification using
proteomic and metabolomic analyses of dormant M. tuberculosis,
low-tech clinical drug susceptibility assay development.
Hanakahi, Les: Assistant Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1996) Yale University
Research interests: The major pathway for DNA Double-Strand Break repair in human cells is Non-Homologous End Joining (NHEJ). The primary focus of my research is to understand, in molecular detail, how DNA ends that are exposed by a DSB are recognized, protected from degradation and efficiently re-joined in human cells. Much of the research being done in my lab centers on the participation of a small molecule, inositol hexakisphosphate (IP6), in the repair of DSBs by mammalian NHEJ. We have found that IP6 is bound by an NHEJ factor and stimulates NHEJ in vitro. This finding opened new possibilities for investigating the molecular mechanism of NHEJ and exciting new avenues for pharmaceutical control of NHEJ in human cells.
Johnson, Michael E.: Professor Emeritus, Department of Medicinal Chemistry and Pharmacognosy, and Director of the Center for Pharmaceutical Biotechnology, Ph.D. (1973) Northwestern University
Research interests: Structural biology of proteins
and RNA; structure-based design of therapeutic agents using modern
techniques of computer-aided drug design, combinatorial expansion,
in silico screening of chemical libraries and related technologies.
Modern biotechnology provides an enormous range of tools for the
development of new therapeutic agents to treat infectious diseases
and other human ailments.
Kozikowski, Alan P.: Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1974) University of California, Berkeley
Research interests: Using the latest methods
of organic synthesis combined with information gleaned from the
methods of molecular modeling (both small molecule and protein
modeling) to design and synthesize molecules that can be used
to gain a better understanding of the function of specific molecular
targets. These chemical tools in turn aid in the design of valuable
diagnostics as well as therapies for treating human diseases including
neurodegenerative conditions and cancer.
Mankin, Alexander S.: Professor, Department of Medicinal Chemistry and Pharmacognosy and the Center for Pharmaceutical Biotechnology, Ph.D. (1981) Moscow State University
Research Interests: Mechanisms of protein synthesis;
structure, function and evolution of ribosome and ribosomal RNA;
mechanisms of action of ribosome-targeted antibiotics.
Moore, Terry W.: Assistant Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (2008) University of Illinois at Urbana-Champaign
Research Interests:Our research group is interested in inhibiting protein-protein interactions implicated in the progression of certain types of cancer, particularly hormone-responsive and -refractory cancers. Specifically, we are interested in inhibiting the Nrf2/Keap1 interaction, an interaction involved in various disease states because of Nrf2’s central role in regulating the cell’s response to reactive species. The second project is focused on inhibiting the interactions of nuclear receptors with coactivators. We study these interactions using fluorescence-based assays, and the lab uses the tools of synthetic medicinal chemistry to develop both small molecule- and peptide-based inhibitors.
Murphy, Brian T.: Assistant Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (2007) Virginia Tech
Research interests: The surfaces of marine organisms provide a source of nutrients for microbes within our oceans. Consequently a competition for space results between surface-colonizing (epibiotic) microorganisms. We propose that select secondary metabolites from epibiotic bacteria, which serve as chemical defenses or means of inter- and intra-species microbial communication, can be utilized to probe and combat the pathogenic mechanisms of human microbial pathogens. In the Murphy lab, these epibiotic bacteria are collected from unique source organisms, cultivated in liquid culture, crudely separated, and screened against a variety of human pathogens with the ultimate intent of discovering novel antibiotic structural classes. Of particular interest is the target Mycobacterium tuberculosis, a pathogen responsible for 1.5 2.3 million deaths in 2008 [WHO Global Tuberculosis Control report]. We work in close collaboration with the Institute for Tuberculosis Research at UIC (http://www.tuberculosisdrugresearch.org/), who has both in vitro and in vivo screening capacity.
Orjala, Jimmy: Associate Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1993) Swiss Federal Institute of Technology (ETH) Zurich, Switzerland.
Research interests: Our research is focused
on three areas: 1. Discovery of pharmacological active natural
products from cultured cyanobacteria. 2. Chemical communication
between microorganisms and its role in the phenomenon of ‘uncultivable’
microorganisms. 3. Novel antineoplastic agents from higher plants.
Our research tools are modern chromatographic methods coupled
with sensitive analytical techniques, such as microcoil NMR techniques,
and molecular target assays.
Pauli, Guido F.: Associate Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1993) Heinrich Heine–University Düsseldorf; Pharm.D., 1988, Philipps University Marburg.
Research interests: Within the realm of modern
pharmacognosy, investigation of traditional as well as novel natural
products by means of chemical, biological, pharmacological and
metabolome analysis. Research tools are computer-aided structure
elucidation, multidimensional and quantitative
NMR, modern chromatographic methods including countercurrent
chromatography, in tandem with in vitro and in
vivo biology and pharmacology as well as microbiological
methods. Relying on this tool chest, research focuses are in phytopharmacy
and phytochemistry, herbal dietary supplements, reference materials,
anti-TB drugs and mycobacterial secondary metabolites.
Petukhov, Pavel A.: Associate Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1998) Novosibirsk Institute of Organic Chemistry, Russia
Research Interests: Development of new methods and biologically orthogonal chemical tools for chemical biology and translation of this knowledge to discovery of novel therapeutically relevant compounds; structure-, ligand-, and fragment-based drug design using a mix of medicinal chemistry, computer-aided drug design, and bioinformatics. The current focus of the laboratory is on the development of methods for characterization of multiple binding modes of the ligands in the binding sites of histone deacetylases (HDAC) using photoactivatable chemical probes and discovery of novel inhibitors of HDACs, calpain, beta-secretases 1 and 2, pantothenate synthetase, and malate synthase with potential application in cancer, neurological and bacterial diseases.
Soejarto, D. Doel: Professor and Director of the Pharmacognosy Field Station, Department of Medicinal Chemistry and Pharmacognosy, and the Department of Biology, Ph.D. (1969) Harvard University
Research interests: Taxonomy and conservation
of plants, with special focus in Southeast Asia, particularly,
Vietnam and Laos, and study of plants used in indigenous therapy,
as well as tropical rainforest explorations of new and potential
medicinal plants (bioprospecting), as part of collaborative research
projects at UIC. I also study the taxonomy of the family Actinidiaceae.
Since 1998, I have been directing an international collaborative
program to study the biodiversity of Vietnam and Laos, as part
of the International Cooperative Biodiversity Groups (ICBG) Program
of the Fogarty International Center, NIH. Our ICBG program activities
include floristics and conservation at Cuc Phuong National Park;
studies of medicinal plants of Laos; biological evaluation of
plants of Vietnam and Laos using anti-HIV, anticancer, anti-TB
and anti-malarial bioassays toward the discovery of biologically
active molecules as potential candidates for pharmaceutical development;
and the promotion of economic development among communities in
Vietnam and Laos, where our ICBG work is being undertaken. Aside
from UIC as base institution, our ICBG consortium members include
Purdue University, Vietnamese Academy of Science and Technology
in Hanoi (Institute of Biotechnology, Institute of Chemistry,
and Institute of Ecology and Biological Resources), Cuc Phuong
National Park (Vietnam), Traditional Medicine Research Center
in Vientiane (Laos), and Bristol-Myers Squibb Co. (industrial
Swanson, Steven M.: Professor, Department of Medicinal Chemistry and Pharmacognosy; Associate Dean for Research and Graduate Education, College of Pharmacy; PhD (1990) University of Illinois at Chicago.
Research interests: The major theme of research by my laboratory is to develop novel therapies for the treatment of breast and prostate cancer. We currently have two federally funded research projects ongoing. “Biological Correlation and Analysis” funded by the NIH. In this core, we evaluate activity of extracts and pure compounds against specific molecular targets. We also conduct follow-up assays on active principles using cell based and animal model systems. Finally, we conduct studies to evaluate the mechanism of action of leads. We currently have two very promising compounds that have been selected by NIH to undergo further preclinical development in the RAID program. Our second federally funded project is supported by the Department of Defense and is entitled “Mechanism of Prostate Cancer Prevention by downregulation of the GH/IGF Axis." Our goal in this project is to further test the hypothesis that the growth hormone/insulin-like growth factor (GH/IGF-1) axis is a good target to develop novel anti-cancer therapeutics against. We think that targeting GH may be safer and more efficacious than targeting IGF-1 since GH regulates IGF-1 and can downregulate IGF-1 substantially, but not completely. However, other therapeutics that downregulate IGF-1 may do so to a degree that could produce harmful side effects.
Thatcher, Gregory R.: Professor and Hans W. Vahlteich Chair in Medicinal Chemistry; Assistant Head, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1986) University of Toronto
Research interests: Employing the tools of mechanistic
organic chemistry and the ability to synthesize novel compounds,
biomimetics are being developed as probes of biological systems.
These mimetics have the capacity to further understanding of biological
processes, chemical toxicology and in some cases to provide new
drug candidates. This program is revealing new therapeutics for
neurological disorders and for cancer.
Thomas, Douglas D.: Associate Professor, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (2000) Louisiana State University
Research interests: Our goal is to elucidate fundamental mechanisms to explain the etiologies of cancer. In addition to gene mutations, aberrant epigenetic modifications also play major roles in cancer development and progression. The primary focus of this lab is to investigate the myriad of abnormal epigenetic modifications that have been associated with tumor phenotype via tumor suppressor silencing or upregulation of oncogenic proteins. Our approach uses both in vitro and in vivo model systems coupled with a multitude of methodologies including mass spectroscopy, confocal microscopy, electron paramagnetic resonance imaging of free radicals, chemiluminescence, electrochemical, and molecular biology techniques. The current emphasis of our team focuses on genome-wide analysis of events leading to the development and ultimate treatment of breast cancer.
van Breemen, Richard B.: Professor, Department of Medicinal Chemistry and Pharmacognosy, Director of the UIC/NIH Center for Dietary Supplements Research, and Assistant to the Director of the Research Resources Center, Ph.D. (1985) The Johns Hopkins University
Research interests: Biomedical applications
of tandem mass spectrometry (MS-MS) and HPLC-MS-MS including the
discovery and development of botanical natural products for cancer
chemoprevention and women's health. We are using mass spectrometry
in all aspects of drug discovery and development from the screening
of plant extracts for the discovery of new therapeutic agents
to in vitro models of drug metabolism and bioavailability studies
in clinical trials.
Woodbury, Charles P.: Associate Professor and Assistant Head, Department of Medicinal Chemistry and Pharmacognosy, Ph.D. (1975) University of Wisconsin.
Research interests: Biophysical chemistry of
proteins and nucleic acids; electrolyte and polyelectrolyte solutions;
macromolecular binding theory; stochastic theory of single molecule
reaction kinetics; statistical theory of chromatography. Studies
in these fundamental areas will help in the future development
of therapeutics and diagnostics.
|Bingel, Audrey S.|
|Cordell, Geoffrey A.|
|Fitzloff, John F.|
|Fong, Harry H.S.|
|Hopfinger, Anton J.|
|Johnson, Michael E.|
|Lu, Matthias C.|
|Name||Research Group Affiliation|
|Cho, Sang Hyun
|Institute for Tuberculosis Research|
|Dietz, Birgit M.
|Graham, James G.
|Jaki, Birgit U.
|Institute for Tuberculosis Research|
|Klein, Larry L.
|Institute for Tuberculosis Research|
|NMR, Shared Laboratory Resources|
|Lankin, David C.
|Movahed Zadeh, Farahnaz
|Institute for Tuberculosis Research|
|Nikolic, Dejan S.
Mass Spec Facility
|Piersen, Colleen E.
|Ratia, Kiira M.
|Santarsiero, Bernard D.
|RRC Macromolecular Structure Facility
RRC Small Molecule X-ray Facility
Center for Pharmaceutical Biotechnology
|Center for Pharmaceutical Biotechnology|
|Angerhofer, Cindy K.
||Aveda Institute / Aveda Corporation|
|Becker, Daniel P.||MDCH 594|
|Block, Keith I.|
|Cox, Paul Alan
|Cullum, Malford E.|
|Dunn, William J.
|Fabricant, Daniel S.
||Division Director, Food and Drug Administration (FDA)|
|Flavin, Michael T.
||Advanced Life Sciences, Inc.|
|Friesen, John B.|
|Hansen, Donald W. Jr.||MDCH 594|
|Kinghorn, A. Douglas||The Ohio State University|
|Marks, William H.||Swedish Medical Center|
|McAlpine, James B.|
|Mesecar, Andrew D.||Purdue University|
|Pang, Yuan-Ping||Mayo Clinic College of Medicine|
|Pezzuto, John M.||University of Hawaii Hilo|
|Pitzele, Barnett S.||MDCH 594, PHAR 331 (Fall 2008-2010)|
|Venton, Duane L.|
|Woodford, Mark M.||MDCH 594|
|Zhou, Zi (Joseph)||Now Foods|